e12654 Background: Standard preoperative systemic therapy for HER2+ breast cancer (BC) patients (pts) includes chemotherapy (CT) and Trastuzumab (T). Two randomized phase II trials, NeoSphere and TRYPHAENA, showed that the addition of Pertuzumab (P) to a T–based neoadjuvant therapy improves the pathologic complete response (pCR) rate, with no evidence that P increased the rate of cardiac dysfunction. Based on these two trials, on June 2015, European Medicine Agency (EMA) approved dual HER2 blockade with T+P for the neoadjuvant treatment of HER2+ BC. PerTe is an observational study, aimed to evaluate the efficacy and safety of P+T as neoadjuvant treatment of HER2+ BC in a real practice setting. Methods: 65 pts treated with P+T+CT as neoadjuvant therapy were identified by 3 Italian Institutions since July 2015. Based on clinical practice of belonging institution, pts were treated with 3 different CT regimens: 1) ECx4 followed by P+T+weekly paclitaxel for 12, 2) ECx4 followed by P+T+docetaxel for 4 cycles and 3) P+T+docetaxel for 6 cycles. The primary objective is to evaluate the pCR rate, defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes. The secondary objective is to evaluate the safety profile of dual HER2 blockade. Results: To date, 48 pts completed the study treatment and underwent surgery, 2 experienced disease progression at the end of neoadjuvant treatment, while 16 pts are still on treatment. Of all evaluable pts, 28 (56%) had a HER2+, Luminal B, ductal infiltrating carcinoma (DCI) and 22 (44%) had a HER2+, Hormone Receptor-negative (HR-) DCI. pCR was achieved in 36 (72%) pts, 12 pts (24%) had residual disease at histologic examination. The highest pCR rate was observed in pts with high level of ki-67 and HR- (86%). No difference was observed among treatment regimens. No significant cardiac toxicity was detected. Conclusions: Neoadjuvant treatment with P+T+CT in a real practice setting is highly effective and does not raise cardiac safety concerns, regardless of the chemotherapy regimen used. We are going to involve more institutions in order to collect a larger sample.